In vitro anti‐tubulin effects of mebendazole and fenbendazole on canine glioma cells

• Published in: Veterinary & comparative oncology 2017-12, Vol.15 (4), p.1445-1454
• Main Authors: Lai, S. R., Castello, S. A., Robinson, A. C., Koehler, J. W.
• Format: Article
• Language: English
• Subjects: Animals; benzimidazole; Blotting, Western - veterinary; canine; Cell Line, Tumor; chemotherapy; Dog Diseases - drug therapy; Dogs; fenbendazole; Fenbendazole - pharmacology; Fenbendazole - therapeutic use; glioma; Glioma - drug therapy; Glioma - veterinary; Male; mebendazole; Mebendazole - pharmacology; Mebendazole - therapeutic use; Tubulin - drug effects; Tubulin Modulators - therapeutic use
• ISSN: 1476-5810; 1476-5829
• DOI: 10.1111/vco.12288

ABSTRACT Benzimidazole anthelmintics have reported anti‐neoplastic effects both in vitro and in vivo. The purpose of this study was to evaluate the in vitro chemosensitivity of three canine glioma cell lines to mebendazole and fenbendazole. The mean inhibitory concentration (IC50) (±SD) obtained from performing the MTT [3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide] assay after treating J3T, G06‐A, and SDT‐3G cells for 72 h with mebendazole were 0.030 ± 0.003, 0.080 ± 0.015 and 0.030 ± 0.006 μM respectively, while those for fenbendazole were 0.550  ± 0.015, 1.530 ± 0.159 and 0.690 ± 0.095 μM; treatment of primary canine fibroblasts for 72 h at IC50 showed no significant effect. Immunofluorescence studies showed disruption of tubulin after treatment. Mebendazole and fenbendazole are cytotoxic in canine glioma cell lines in vitro and may be good candidates for treatment of canine gliomas. Further in vivo studies are required.